Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Invest Ophthalmol Vis Sci ; 60(13): 4097-4108, 2019 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-31574535

RESUMEN

Purpose: Investigate a significant, dose-related increase in IOP, leading to glaucomatous damage to the neuroretina and optic nerve following intravitreal (ITV) administration of a bispecific F(ab')2 [anti-VEGF/Angiopoietins [ANGPT]F(ab')2] molecule in adult monkeys. Methods: ITV ocular tolerability and investigation of anti-VEGF/ANGPT F(ab')2 (blocking both ANGPT1 and ANGPT2) was done in monkeys; mechanistic studies were done in neonatal mice. Results: Following the second ITV dose of anti-VEGF/ANGPT F(ab')2, all 1.5- and 4-mg/eye treated monkeys developed elevated IOP, which eventually was associated with optic disc cupping and thinning of the neuroretinal rim. Histopathologic examination showed nonreversible axonal degeneration in the optic nerves of animals administered 1.5 mg/eye and higher that was considered secondary to high IOP. Anti-ANGPT Fab also caused elevated IOP in monkeys, but anti-VEGF Fab did not contribute to the IOP increase. In addition, an anti-ANGPT2-selective antibody did not change IOP. In mice simultaneous blockade of ANGPT1 and ANGPT2 impaired the expansion and formation of Schlemm's canal (SC) vessels, similar to genetic ablation of Angpt1/Angpt2 and their receptor TIE2. As previously reported, blocking ANGPT2 alone did not affect SC formation in mice. Conclusions: Dual inhibition of ANGPT1/ANGPT2, but not ANGPT2 alone, leads to increased IOP and glaucomatous damage in monkeys. This confirms a role for TIE2/ANGPT signaling in the control of IOP in adults, a finding initially identified in transgenic mice. Dual pharmacologic inhibition of ANGPT1/ANGPT2 may affect aqueous drainage and homeostasis in adult monkeys and may be useful in developing novel models of glaucoma.


Asunto(s)
Angiopoyetina 1/antagonistas & inhibidores , Angiopoyetina 2/antagonistas & inhibidores , Humor Acuoso/metabolismo , Glaucoma/fisiopatología , Transducción de Señal/fisiología , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Angiopoyetina 1/fisiología , Angiopoyetina 2/fisiología , Animales , Anticuerpos/farmacología , Presión Intraocular , Primates , Factor A de Crecimiento Endotelial Vascular/fisiología
2.
Saudi Med J ; 34(6): 584-90, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23756922

RESUMEN

OBJECTIVES: To observe the potential protective effect of angiopoietin-1 (Ang-1) on rat choroidal neovascularization (CNV) leakage. METHODS: The study was conducted at the Eye Institute of Shandong University of Traditional Chinese Medicine, Jinan, China from June 2012 to June 2013. Thirty CNV model rats were induced by laser. In vivo, fluorescein fundus angiography and pathological techniques were applied to detect the effect of vascular endothelial growth factor (VEGF) and Ang-1 intravitreous injection. In vitro, 3-(4, 5-dimethylthiazole-2-yl)-2, 5-biphenyl tetrazolium bromide (MTT) assay was applied to detect the proliferation of cultured bovine retinal endothelial cells (BRECs) after treatment with VEGF and Ang-1. Transmission electron microscopy (TEM) was used to detect the morphological changes under VEGF and Ang-1. RESULTS: In the CNV rat model, less late leakage was found in the Ang-1 group than the vehicle control or the VEGF group. The MTT assay showed Ang-1 administration inhibited the proliferation of BRECs. The VEGF promoted proliferation at low concentrations and inhibited the proliferation when its concentration reached 50 ng/ml. The administration of VEGF+Ang-1 rescued the inhibition effect of Ang-1 alone. The TEM results showed that there were less intercellular junctions in the VEGF group compared with the vehicle control. In the VEGF + Ang-1 group, the intercellular junctions were nearly normal. CONCLUSION: The Ang-1 can induce intercellular junction formation and decrease the CNV leakage.


Asunto(s)
Angiopoyetina 1/fisiología , Neovascularización Coroidal/fisiopatología , Animales , Bovinos , Proliferación Celular , Células Cultivadas , Femenino , Angiografía con Fluoresceína , Microscopía Electrónica de Transmisión , Ratas , Retina/citología , Factor A de Crecimiento Endotelial Vascular/fisiología
3.
J Clin Invest ; 121(6): 2157-9, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21606600

RESUMEN

Twenty years after the discovery of the vascular endothelial Tie receptor tyrosine kinases and 15 years after the discovery of the Tie2 ligand, angiopoietin-1 (Angpt1, also known as Ang1), a study published in the current issue of the JCI reveals an unexpected loss-of-function phenotype of mice conditionally deleted of the Angpt1 gene. The results suggest that Angpt1 is needed as a vascular stabilizing factor that organizes and limits the angiogenesis response and protects from pathological consequences, such as tissue fibrosis.


Asunto(s)
Angiopoyetina 1/fisiología , Neovascularización Fisiológica/fisiología , Angiopoyetina 1/deficiencia , Angiopoyetina 1/genética , Angiopoyetina 2/fisiología , Animales , Vasos Sanguíneos/embriología , Capilares/citología , Capilares/crecimiento & desarrollo , Permeabilidad Capilar , Adhesión Celular , Supervivencia Celular , Células Endoteliales/citología , Fibrosis , Humanos , Ratones , Ratones Noqueados , Modelos Cardiovasculares , Miocitos Cardíacos/patología , Miocitos Cardíacos/fisiología , Neoplasias/irrigación sanguínea , Neovascularización Patológica/embriología , Neovascularización Patológica/genética , Neovascularización Patológica/patología , Neovascularización Patológica/fisiopatología , Neovascularización Fisiológica/genética , Pericitos/metabolismo , Proteínas Tirosina Quinasas Receptoras/fisiología , Receptor TIE-1/fisiología , Receptor TIE-2
4.
Circulation ; 110(15): 2220-5, 2004 Oct 12.
Artículo en Inglés | MEDLINE | ID: mdl-15466636

RESUMEN

BACKGROUND: The phosphodiesterase type-5 (PDE-5) inhibitor sildenafil has been reported to improve pulmonary arterial hypertension (PAH), but the mechanisms that account for this effect are incompletely understood. Severe pulmonary hypertension has been characterized by defects in a signaling pathway involving angiopoietin-1 and the bone morphogenetic receptor-2 (BMPR-2). We investigated the effects of sildenafil on hemodynamics and signaling molecules in a piglet overcirculation-induced model of early PAH. METHODS AND RESULTS: Thirty 3-week-old piglets were randomized to placebo or sildenafil therapy 0.75 mg/kg TID after anastomosis of the left subclavian artery to the pulmonary arterial trunk or after a sham operation. Three months later, the animals underwent a hemodynamic evaluation followed by pulmonary tissue sampling for morphometry, immunohistochemistry or radioimmunoassay, and real-time quantitative-polymerase chain reaction. Chronic systemic-to-pulmonary shunting increased pulmonary mRNA for angiopoietin-1, endothelin-1 (ET-1), angiotensin II, inducible nitric oxide synthase, vascular endothelial growth factor, and PDE-5. Pulmonary messenger RNA for BMPR-1A and BMPR-2 decreased. Pulmonary angiotensin II, ET-1, and vascular endothelial growth factor proteins increased. Pulmonary artery pressure increased from 20+/-2 to 33+/-1 mm Hg, and arteriolar medial thickness increased by 91%. The expressions of angiopoietin-1, ET-1, and angiotensin II were tightly correlated to pulmonary hypertension. Sildenafil prevented the increase in pulmonary artery pressure, limited the increase in medial thickness to 41%, and corrected associated biological perturbations except for the angiopoietin-1/BMPR-2 pathway, PDE-5, and angiotensin II. CONCLUSIONS: Sildenafil partially prevents overcirculation-induced PAH and associated changes in signaling molecules. Angiotensin II, PDE-5, and angiopoietin-1/BMPR-2 signaling may play a dominant role in the early stages of the disease.


Asunto(s)
Angiopoyetina 1/fisiología , Hipertensión Pulmonar/prevención & control , Inhibidores de Fosfodiesterasa/uso terapéutico , Piperazinas/uso terapéutico , Proteínas Serina-Treonina Quinasas/fisiología , Transducción de Señal/efectos de los fármacos , 3',5'-GMP Cíclico Fosfodiesterasas , Anastomosis Quirúrgica/efectos adversos , Angiopoyetina 1/biosíntesis , Angiopoyetina 1/genética , Angiotensina II/biosíntesis , Angiotensina II/genética , Animales , Arteriolas/ultraestructura , Receptores de Proteínas Morfogenéticas Óseas de Tipo 1 , Receptores de Proteínas Morfogenéticas Óseas de Tipo II , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5 , Evaluación Preclínica de Medicamentos , Endotelina-1/biosíntesis , Endotelina-1/genética , Regulación de la Expresión Génica/efectos de los fármacos , Hiperplasia , Hipertensión Pulmonar/etiología , Hipertensión Pulmonar/metabolismo , Modelos Animales , Óxido Nítrico Sintasa/biosíntesis , Óxido Nítrico Sintasa/genética , Óxido Nítrico Sintasa de Tipo II , Inhibidores de Fosfodiesterasa/farmacología , Hidrolasas Diéster Fosfóricas/biosíntesis , Hidrolasas Diéster Fosfóricas/efectos de los fármacos , Hidrolasas Diéster Fosfóricas/genética , Piperazinas/farmacología , Proteínas Serina-Treonina Quinasas/biosíntesis , Proteínas Serina-Treonina Quinasas/genética , Arteria Pulmonar/cirugía , Purinas , ARN Mensajero/biosíntesis , Distribución Aleatoria , Receptores de Factores de Crecimiento/biosíntesis , Receptores de Factores de Crecimiento/genética , Citrato de Sildenafil , Arteria Subclavia/cirugía , Sulfonas , Sus scrofa , Factor A de Crecimiento Endotelial Vascular/biosíntesis , Factor A de Crecimiento Endotelial Vascular/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA